GlassScriptPhysician profile
William C Bryant
NPI 1821609082
$6,928.53
in general payments reported to CMS, 2019-2025
33 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,888 · 2022: $1,741 · 2023: $983 · 2024: $1,231 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,005.88 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Novartis Pharmaceuticals Corporation | $968.46 | 2021-2025 | |
| Amgen INC. | $933.45 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $620.14 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.58 | 2021-2025 | Jardiance |
| Pfizer INC. | $464.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $384.12 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $343.63 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $323.16 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $285.42 | 2021-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $201.35 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $153.14 | 2023-2024 | Inpefa |
| Heartflow, INC. | $119.44 | 2024 | |
| Genzyme Corporation | $106.72 | 2022-2024 | |
| Novo Nordisk INC | $102.56 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $66.60 | 2021-2024 | |
| Boston Scientific Corporation | $41.82 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor |
| Kowa Pharmaceuticals America, INC. | $36.81 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.95 | 2025 | Amvuttra |
| Corcym INC | $33.09 | 2023 | Miami Instruments |
| Arbor Pharmaceuticals, INC. | $23.66 | 2021 | |
| Bardy Diagnostics, INC. | $23.00 | 2022 | |
| Shockwave Medical, INC | $22.84 | 2022 | |
| Inspire Medical Systems, INC. | $21.68 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $18.27 | 2024 | Arcalyst |
| Abiomed | $17.86 | 2025 | |
| Chiesi USA, INC. | $17.77 | 2023 | Kengreal |
| Amryt Pharma Holdings LTD | $17.54 | 2021 | |
| Daiichi Sankyo INC. | $16.70 | 2023 | Injectafer |
| Biotronik INC. | $15.08 | 2021 | |
| Stryker Corporation | $14.62 | 2024 | Na |
| Janssen Biotech, INC. | $11.81 | 2021 | |
| Biobeat USA INC. | $5.10 | 2024 | Bb-613 Bpm Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.